Active Biotech Presents Data regarding the 57-57 Project at EULAR

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data from an exploratory
clinical trial in Systemic Lupus Erythematosus (SLE) patients at the Annual
European Congress of Rheumatology EULAR 2011, an international event for
specialists in the field of rheumatology, held in London May 25-28*.

In the clinical SLE trial, patients were treated daily with oral 57-57 for 12
weeks as add-on to standard therapy. The objectives of the study were to assess
changes in disease activity and biomarkers as well as safety. Improvement of SLE
symptoms was seen in patients with arthritis, oral ulcers and/or alopecia.
Changes in PBMC gene expression profiles relevant for autoimmune diseases could
also be detected. The overall safety profile was favorable.

The next step in the development of 57-57 is an explorative clinical study
in patients with Systemic Sclerosis which is planned to start during 2011.

Lund, May 26, 2011

Active Biotech AB (Publ)

Tomas Leanderson
President & CEO

* For further information and to take part of the complete poster "An
Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During
Treatment with ABR-215757 in Patients with Mild Active Systemic Lupus
Erythematosus (SLE)", please visit

About SLE and 57-57
SLE  -  Systemic  Lupus  Erythematosus  (SLE)  -  is  a  disease  that can cause
inflammation  and damage to the connective  tissue in many different organs. The
disease, which progresses in "flare-ups" interspersed by relatively symptom-free
periods,  primarily  affects  women  of  childbearing age. An estimated 500,000
Americans  have  been  diagnosed  with  SLE;  however, surveys indicate that the
prevalence  may be  much higher.  The autoimmune  attack affects  many different
organ  systems and  may eventually  lead to  severe secondary  symptoms, such as
kidney  failure. Progress and symptoms of  the disease vary widely, depending on
the organs affected. Without treatment, SLE can be life-threatening.

57-57 is  a quinoline compound originally intended for the treatment of SLE.  In
August  2010, Active Biotech decided  to initiate the  development of 57-57 also
for  the treatment  of Systemic  Sclerosis (SSc).  In February  2011, the 57-57
project  was granted orphan medicinal product status for the indication Systemic
Sclerosis. An explorative clinical study in SSc is planned to start during 2011.

About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory  properties for the  treatment of multiple  sclerosis, TASQ for
prostate  cancer and  ANYARA for  use in  cancer targeted  therapy, primarily of
renal  cell  cancer.  In  addition,  laquinimod  is  in Phase II development for
Crohn's  and Lupus.  Further projects  in clinical  development comprise the two
orally  administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.comfor more information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active  Biotech  is  required  under  the  Securities  Markets  Act  to make the
information  in this  press release  public. The  information was  submitted for
publication at 08:30 am CET on May 26, 2011.

Active Biotech Presents Data regarding the 57-57 Project at EULAR:

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE